Information Provided By:
Fly News Breaks for October 13, 2015
HTWR
Oct 13, 2015 | 11:31 EDT
Credit Suisse lowered HeartWare's price target to $34 from $90 after the company indicated that its MVAD trial might not be starting up in November as originally planned. Analyst Matthew Keeler said he lacks insight into the duration of the trial delay and whether this MVAD enrollment pause represents a material adverse event that might allow Valtech to walk away from the HTWR acquisition though it would seem to be reasonable grounds. Keeler has an Outperform rating on Heartware shares.
News For HTWR From the Last 2 Days
There are no results for your query HTWR